Side Effects of Drugs Annual, Volume 35

Contributors
Special reviews in SEDA-35
Cumulative indexes of special reviews, Annuals 4–34
1 Index of medications in special reviews

2 Index of adverse effects and adverse reactions in special reviews

Table of Essays, Annuals 1–34
Mechanistic and clinical descriptions of adverse drug reactions
1 EIDOS

2 DoTS

Definitive (between-the-eyes) adverse drug reactions
How to use this book
The scope of the Side Effects of Drugs Annuals

Period covered

Selection of material

Allocation of drugs to chapters

Names of drugs and chemicals

System of tagging references

Indexes

Abbreviations
35 years of the Side Effects of Drugs Annuals—a tribute to our contributors
Classification of immunological reactions
Classification of drug teratogenicity
Grades of adverse drug reactions
Side effects of drugs essay
Abstract

Chapter 1: Central nervous system stimulants and drugs that suppress appetite
Abstract

Amphetamines [SED-15, 180; SEDA-32, 1; SEDA-33, 1; SEDA-34, 1]

Methylxanthines

Drugs That Suppress Appetite [SEDA-32, 16; SEDA-33, 13; SEDA-34, 8]

Drugs Used in Alzheimer’s Disease [SEDA-32, 19; SEDA-33, 15; SEDA-34, 9]

Chapter 2: Antidepressant drugs
Abstract

General

Selective Serotonin Re-uptake Inhibitors (SSRIs) [SED-15, 3109; SEDA-32, 33; SEDA-33, 26; SEDA-34, 37]

Serotonin and Noradrenaline Re-uptake Inhibitors (SNRIs)

Tricyclic Antidepressants

Monoamine Oxidase Inhibitors

Other Antidepressants

Chapter 3: Lithium
Abstract

Chapter 4: Drugs of abuse
Abstract

Cannabinoids [SED-15, 614; SEDA-32, 55; SEDA-33, 55; SEDA-34, 33]

Opioid Analgesics

Chapter 5: Hypnosedatives and anxiolytics
Abstract

Azaspirones [SEDA-32, 75; SEDA-33, 71; SEDA-34, 45]

Benzodiazepines [SED-15, 429; SEDA-32, 75; SEDA-33, 45]

Benzodiazepine-Like Drugs

Benzodiazepine Antagonists

Other Hypnosedatives

Chapter 6: Antipsychotic drugs
Abstract

General [SED-15, 2438; SEDA-32, 83; SEDA-33, 89; SEDA-34, 51]

Individual Drugs

Chapter 7: Antiepileptic drugs
Abstract

Chapter 8: Opioid analgesics and narcotic antagonists
Abstract

General

Opioid Receptor Agonists

Partial Opioid Receptor Agonists

Opioid Receptor Antagonists

Chapter 9: Anti-inflammatory and antipyretic analgesics and drugs used in gout
Abstract

Amidopyrine and Related Compounds

Aniline Derivatives [SED-15, 2679; SEDA-33, 244; SEDA-34, 184]

Non-steroidal Anti-inflammatory Drugs

Anthranilic Acid Derivatives

Arylalkanoic Acid Derivatives [SED-15, 2555; SEDA-32, 229; SEDA-33, 245; SEDA-34, 185]

COX-2 Selective Inhibitors [SEDA-32, 232; SEDA-33, 246; SEDA-34, 186]

Oxicams [SEDA-15, 2555; SEDA-32, 233; SEDA-33, 247; SEDA-34, 187]

Pyrazolone Derivatives (Phenylbutazone and Related Compounds) [SEDA-27, 111]

Salicylates [SED-15, 15; SEDA-33, 248; SEDA-34, 188]

Miscellaneous Drugs

Drugs Used in the Treatment of Gout

Chapter 10: General anesthetics and therapeutic gases
Abstract

Anesthetic Vapors [SEDA-32, 243; SEDA-33, 257; SEDA-34, 195]

Other Vapors

Intravenous Agents: Non-barbiturate Anesthetics

Intravenous Agents: Barbiturate Anesthetics

Chapter 11: Local anesthetics
Abstract

General

Effects Related to Modes of Use [SED-15, 2121; SEDA-32, 262; SEDA-33, 281; SEDA-34, 209]

Caudal, Epidural, and Spinal Anesthesia

Individual Compounds

Chapter 12: Neuromuscular blocking agents and skeletal muscle relaxants
Abstract

Depolarizing Neuromuscular Blocking Agents

Non-depolarizing Neuromuscular Blocking Agents [SED-15, 2489; SEDA-32, 274; SEDA-33, 301; SEDA-34, 222]

Skeletal Muscle Relaxants

Chapter 13: Drugs that affect autonomic functions or the extrapyramidal system
Abstract

Drugs That Stimulate Both Alpha- and Beta-Adrenoceptors [SEDA-32, 281; SEDA-33, 313; SEDA-34, 233]

Drugs That Predominantly Stimulate Alpha1-Adrenoceptors [SEDA-32, 283; SEDA-33, 318; SEDA-34, 236]

Drugs That Stimulate Beta1-Adrenoceptors [SEDA-32, 284; SEDA-33, 265; SEDA-34, 240]

Drugs That Stimulate Beta2-Adrenoceptors [SEDA-34, 241]

Drugs That Stimulate Dopamine Receptors [SEDA-33, 266; SEDA-34, 342]

Drugs That Stimulate Dopamine Receptors

Other Drugs That Increase Dopamine Activity

Drugs That Affect the Cholinergic System [SEDA-32, 290; SEDA-33, 324; SEDA-34, 246]

Chapter 14: Dermatological drugs, topical agents, and cosmetics
Abstract

Cosmetics

Dermal Fillers

Dyestuffs [SEDA-15, 1573; SEDA-32, 296]

Fragrances

Glucocorticoids, Topical

Phototherapy and Photochemotherapy [SED-15, 2823; SEDA-32, 297; SEDA-34, 262]

Sunscreens [SED-15, 3248; SEDA-34, 263]

Vitamin A (Retinoids) [SED-15, 3653; SEDA-32, 298; SEDA-34, 264; for vitamin A carotenoids see Chapter 34]

Vitamin D Analogues, Topical [SED-15, 594; SEDA-32, 301; SEDA-34, 265; for oral Vitamin D analogues see Chapter 34]

Devices

Chapter 15: Antihistamines (H1 receptor antagonists)
Abstract

General

Other Antihistamines

Chapter 16: Drugs that act on the respiratory tract
Abstract

Inhaled Glucocorticoids [SEDA -32, 311; SEDA -33, 353; SEDA -34, 277]

Nasal Glucocorticoids [SEDA -34, 279]

Beta2-Adrenoceptor Agonists [SEDA -32, 314; SEDA -33, 357; SEDA -34, 280]

Anticholinergic Drugs [SEDA -32, 318; SEDA -33, 363; SEDA -34, 282]

Leukotriene Modifiers [SEDA -32, 319; SEDA -33, 366; SEDA -34, 283]

Phosphodiesterase Type IV Inhibitors [SEDA -32, 321; SEDA -33, 367; SEDA -34, 284]

Mucolytic Drugs [SEDA -32, 325; SEDA -33, 369]

Antitussive Drugs

Chapter 17: Positive inotropic drugs and drugs used in dysrhythmias
Abstract

Cardiac Glycosides [SED-15, 648; SEDA-32, 333; SEDA-33, 377; SEDA-34, 287]

Other Positive Inotropic Drugs [SED-15, 2822; SEDA-31, 323; SEDA-32, 336; SEDA-33, 378]

Antidysrhythmic Drugs

Adenosine Receptor Agonists [SEDA-32, 337; SEDA-33, 379; SEDA-34, 292]

Chapter 18: Beta-adrenoceptor antagonists and antianginal drugs
Abstract

Beta-Adrenoceptor Antagonists [SED-15, 452; SEDA-32, 363; SEDA-33, 397; SEDA-34, 303]

Potassium Channel Activators

Nitrates, Organic [SED-15, 2529; SEDA-32, 366; SEDA-33, 400; SEDA-34, 305]

Calcium Channel Blockers [SED-15, 598; SEDA-32, 366; SEDA-33, 401; SEDA-34, 306]

Chapter 19: Drugs acting on the cerebral and peripheral circulations
Abstract

Drugs Used in the Treatment of Arterial Disorders of the Brain and Limbs

Drugs Used in the Treatment of Venous Disorders

Drugs Used in the Treatment of Migraine

Other Peripheral Vasodilators

Chapter 20: Antihypertensive drugs
Abstract

General

Angiotensin Converting Enzyme (ACE) Inhibitors [SED-15, 226; SEDA -32, 379; SEDA -33, 416; SEDA-34, 321]

Angiotensin II Receptor Antagonists [SED-15, 223; SEDA-32, 387; SEDA-33, 418; SEDA-34, 325]

Dual Angiotensin II Receptor Antagonists/Neprilysin Antagonists

Direct Renin Inhibitors [SEDA-32, 388; SEDA-33, 420; SEDA-34, 328]

Endothelin Receptor Antagonists [SED-15, 1215; SEDA-32, 389; SEDA-33, 421; SEDA-34, 328]

Drugs That Act on the Sympathetic Nervous System [SEDA-32, 391; SEDA-33, 424; SEDA-34, 329]

Non-selective α-Adrenoceptor Antagonists

Postsynaptic α-Adrenoceptor Antagonists [SEDA-32, 391; SEDA-33, 425; SEDA-34, 330]

Imidazoline Receptor Agonists

Direct Vasodilators

Chapter 21: Diuretics
Abstract

Carbonic Anhydrase Inhibitors [SED-15, 643; SEDA-32, 403; SEDA-33, 437; SEDA-34, 339]

Thiazide and Thiazide-Like Diuretics [SED-15, 3375; SEDA-32, 405; SEDA-33, 438; SEDA-34, 340]

Loop Diuretics [SED-15, 567, 1454; SEDA-32, 408; SEDA-33, 440; SEDA-34, 342]

Aldosterone Receptor Antagonists

Osmotic Diuretics

Chapter 22: Metals
Abstract

Chapter 23: Metal antagonists
Abstract

Iron Chelators

Penicillamine and Related Drugs [SED-15, 2729; SEDA-32, 430; SEDA-33, 472; SEDA-34, 372]

Other Chelators

Polystyrene Sulfonates [SED-15, 2894; SEDA-32, 433; SEDA-33, 474; SEDA-34, 373]

Chapter 24: Antiseptic drugs and disinfectants
Abstract

Aldehydes [SED-15, 1439, 1513; SEDA-32, 437; SEDA-33, 479; SEDA-34, 377]

Bisbiguanides

Boric Acid

Cationic Surfactants

Halogens

Iodophors [SED-15, 1896; SEDA-32, 440; SEDA-33, 485; SEDA-34, 380]

Phenols [SED-15, 2800, SEDA-32, 441; SEDA-33, 485; SEDA-34, 381]

Chapter 25: Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines
Abstract

Beta-Lactam Antibiotics [SED-15, 478; SEDA-32, 447; SEDA-33, 491; SEDA-34, 385]

Cephalosporins [SED-15, 688; SEDA-32, 448; SEDA-33, 493; SEDA-34, 386]

Monobactams and Monocarbams [SED-15, 2378; SEDA-32, 450; SEDA-33, 494; SEDA-34, 388]

Penicillins [SED-15, 2756; SEDA-32, 450; SEDA-33, 495; SEDA-34, 388]

Tetracyclines and Glycylcyclines [SED-15, 3330; SEDA-32, 451; SEDA-33, 497; SEDA-34, 391]

Chapter 26: Miscellaneous antibacterial drugs
Abstract

Aminoglycosides [SED-15, 118; SEDA-32, 461; SEDA-33, 509; SEDA-34, 399]

Fluoroquinolones [SED-15, 1396; SEDA-32, 464; SEDA-33, 514; SEDA-34, 401]

Glycopeptides [SEDA-32, 469; SEDA-33, 519; SEDA-34, 405]

Ketolides [SED-15, 1976; SEDA-32, 471; SEDA-33, 521; SEDA-34, 407]

Lincosamides [SED-15, 2063; SEDA-32, 472; SEDA-33, 522; SEDA-34, 407]

Macrolides [SED-15, 2183; SEDA-32, 472; SEDA-33, 522; SEDA-34, 408]

Nitrofurantoin [SED-15, 2542; SEDA-32, 476, SEDA-33, 525; SEDA-34, 409]

Oxazolidinones [SED-15, 2645; SEDA-32, 474; SEDA-33, 525; SEDA-34, 409]

Polymyxins [SED-15, 2891; SEDA-32, 476; SEDA-33, 527; SEDA-34, 412]

Streptogramins [SED-15, 3182; SEDA-32, 528; SEDA-34, 413]

Sulfonamides, Trimethoprim, and Co-trimoxazole [SED-15, 3216, 3510; SEDA-32, 477; SEDA-33, 528; SEDA-34, 414]

Other Antimicrobial Drugs

Chapter 27: Antifungal drugs
Abstract

Allylamines [SEDA -32, 491; SEDA -33, 541; SEDA -34, 427]

Amphotericin [SED -15, 192; SEDA -32, 493; SEDA -33, 542; SEDA -34, 427]

Antifungal Azoles [SED -15, 301; SEDA -32, 497; SEDA -33, 545; SEDA -34, 428]

Echinocandins [SED -15, 1197; SEDA -32, 507; SEDA -33, 556; SEDA -34, 434]

Chapter 28: Antiprotozoal drugs
Abstract

Antimalarial Drugs

4-Aminoquinolines (Chloroquine and Congeners) [SEDA-32, 521; SEDA-33, 567; SEDA-34, 441]

Pyrimethamine and Combinations [SED-15, 2984; SEDA-32, 523; SEDA-33, 570]

Primaquine and Congeners [SED-15, 2919; SEDA-33, 569; SEDA-34, 442]

Quinine and Congeners [SED-15, 3002; SEDA-32, 524; SEDA-33, 570]

Endoperoxides [SED-15, 342; SEDA-32, 525; SEDA-33, 571; SEDA-34, 442]

Drugs Used in the Treatment of Other Protozoal Infections

Chapter 29: Antiviral drugs
Abstract

Drugs Active Against Cytomegalovirus

Drugs Active Against Herpesviruses [SEDA-32, 530; SEDA-33, 577; SEDA-34, 450]

Drugs Active Against Hepatitis Viruses

Direct-Acting Antiviral Protease Inhibitors

Drugs Active Against Human Immunodeficiency Virus: Combinations

Drugs Active Against Human Immunodeficiency Virus: Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) [SED-15, 2586; SEDA-32, 534; SEDA-33, 585; SEDA-34, 456]

Drugs Active Against Human Immunodeficiency Virus: Nucleotide Analogue Reverse Transcriptase Inhibitors

Drugs Active Against Human Immunodeficiency Virus: Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) [SED-15, 2553; SEDA-32, 537; SEDA-33, 590; SEDA-34, 459]

Drugs Active Against Human Immunodeficiency Virus: Protease Inhibitors [SED-15, 2586; SEDA-32, 541; SEDA-33, 593; SEDA-34, 461]

Drugs Active Against Human Immunodeficiency Virus: Inhibitors of HIV Fusion [SEDA-33; 598; SEDA-34, 464]

Drugs Active Against Human Immunodeficiency Virus: Integrase Inhibitors [SEDA-33, 599; SEDA-34, 465]

Drugs Active Against Human Immunodeficiency Virus: Chemokine Receptor CCR5 Antagonists [SEDA-33, 600; SEDA-34, 465]

Drugs Active Against Influenza Viruses: Neuraminidase Inhibitors [SED-15, 2436; SEDA-32, 544; SEDA-33, 601; SEDA-34, 466]

Drugs Active Against Influenza Viruses: Ion Channel Inhibitors [SED-15, 105, 3051; SEDA-32, 544; SEDA-33, 269, 602; SEDA-34, 467]

Other Drugs

Chapter 30: Drugs used in tuberculosis and leprosy
Abstract

Rifamycins [SED-15, 3040; SEDA-32, 563; SEDA-33, 637; SEDA-34, 484]

Chapter 31: Antihelminthic drugs
Abstract

Benzimidazoles [SED -15, 424; SEDA -32, 572; SEDA -33, 647; SEDA -34, 487]

Chapter 32: Vaccines
Abstract

General

Bacterial Vaccines

Viral Vaccines

Measles, Mumps, and Rubella Vaccines

Other Components of Vaccines

Chapter 33: Blood, blood components, plasma, and plasma products
Abstract

Albumin and Derivatives [SED-15, 54; SEDA-32, 591; SEDA-33, 670; SEDA-34, 509]

Blood Transfusion [SED-15, 529; SEDA-32, 593; SEDA-33, 671; SEDA-34, 509]

Blood Substitutes [SEDA-32, 593; SEDA-33, 672; SEDA-34, 511]

Plasma and Plasma Products [SED-15, 2847; SEDA-32, 594; SEDA-33, 674; SEDA-34, 512]

Plasma Substitutes [SEDA-32, 594; SEDA-33, 675; SEDA-34, 513]

Globulins

Coagulation Proteins [SED-15, 845; SEDA-32, 596; SEDA-33, 679; SEDA-34, 518]

Erythropoietin and Derivatives [SED-15, 1243; SEDA-32, 597; SEDA-33, 681; SEDA-34, 520]

Stem Cells [SEDA-32, 599; SEDA-33, 682; SEDA-34, 522]

Chapter 34: Vitamins, amino acids, and drugs and formulations used in nutrition
Abstract

Vitamin A (Carotenoids) [SED-15, 3642; SEDA-32, 607; SEDA-33, 691; SEDA-34, 531]

Vitamins of the B Group [SED-15, 1432, 3668; SEDA-32, 608; SEDA-33, 693; SEDA-34, 531]

Vitamin C (Ascorbic Acid) [SED-15, 351; SEDA-32, 611; SEDA-33, 694; SEDA-34, 531]

Vitamin D Analogues [SED-15, 3669; SEDA-32, 612; SEDA-33, 695; SEDA-34, 532]

Vitamin E (Tocopherol) [SED-15, 3677; SEDA-32, 612; SEDA-33, 696; SEDA-34, 533]

Vitamin K Analogues [SED-15, 3681; SEDA-34, 533]

Amino Acids

Enteral and Parenteral Nutrition [SED-15, 1221, 2700; SEDA-32, 613; SEDA-33, 697; SEDA-34, 536]

Chapter 35: Drugs that affect blood coagulation, fibrinolysis, and hemostasis
Abstract

Coumarin Anticoagulants [SED-15, 983; SEDA-32, 617; SEDA-33, 707; SEDA-34, 541]

Heparins [SED-15, 1590; SEDA-32, 626; SEDA-33, 713; SEDA-34, 543]

Direct Thrombin Inhibitors [SED-15, 1142; -32, 632; SEDA-33, 717; SEDA-34, 544]

Direct Factor Xa Inhibitors [SEDA-32, 635; SEDA-34, 546]

Indirect Factor Xa Inhibitors [SEDA-32, 636; SEDA-33, 636; SEDA-34, 547]

Thrombolytic Drugs [SED-15, 3402]

Drugs that Alter Platelet Function [SEDA-32, 637; SEDA-33, 637; SEDA-34, 547]

Glycoprotein IIb-IIIa Inhibitors [SED-15, 4; SEDA-32, 638; SEDA-33, 720; SEDA-34, 548]

Thienopyridines [SED-15, 821; SEDA-32, 639; SEDA-33, 720; SEDA-34, 548]

Hemostatic Agents

Chapter 36: Gastrointestinal drugs
Abstract

Antacids [SED-15, 243; SEDA-32, 665; SEDA-33, 741; SEDA-34, 555]

Antiemetics and Drugs That Affect Gastrointestinal Motility [SEDA-32, 665; SEDA-33, 741; SEDA-34, 555]

5HT3 Receptor Antagonists [SED-15, 1365; SEDA-32, 666; SEDA-33, 744; SEDA-34, 559]

Neurokinin NK1 Receptor Antagonists [SEDA-32, 667; SEDA-33, 748; SEDA-34, 561]

Histamine H2 Receptor Antagonists [SED-15, 1629; SEDA-32, 667; SEDA-33, 748; SEDA-34, 562]

Proton Pump Inhibitors [SED-15, 2973; SEDA-32, 667; SEDA-33, 749; SEDA-34, 563]

Helicobacter Pylori Eradication Regimens [SEDA-33, 749]

Other Ulcer-Healing Agents

Cholelitholytic Agents

Laxatives and Oral Bowel Preparations [SED-15, 2008; SEDA-32, 668; SEDA-33, 753; SEDA-34, 569]

Bowel Secretagogues

Aminosalicylates [SED-15, 138; SEDA-32, 669; SEDA-33, 756; SEDA-34, 571]

Antispasmodic Agents

Antidiarrheal Agents

Probiotics

Other Gastrointestinal Agents

Chapter 37: Drugs that act on the immune system: cytokines and monoclonal antibodies
Abstract

Colony-Stimulating Factors [SEDA-32, 675; SEDA-33, 769; SEDA-34, 581]

Interferons [SED-15, 1841; SEDA-32, 676; SEDA-33, 773; SEDA-34, 581]

Interleukins [SED-15, 1831; SEDA-32, 676; SEDA-33, 777; SEDA-33, 771]

Tumor Necrosis Factor Alfa (TNF-α) and Its Antagonists [SEDA-32, 677; SEDA-33, 779; SEDA-34, 583]

VEGF Antagonists

Monoclonal Antibodies [SED-15, 2380; SEDA-32, 686; SEDA-33, 783; SEDA-34, 586]

Chapter 38: Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs
Abstract

Thiopurines [SED-15, 377; SEDA-32, 717; SEDA-33, 824; SEDA-34, 633]

Immunoenhancing Drugs

Chapter 39: Corticotrophins, corticosteroids, and prostaglandins
Abstract

Corticotrophins [SED-15, 906; SEDA-32, 723; SEDA-33, 841; SEDA-34, 653]

Systemic Glucocorticoids [SED-15, 906; SEDA-32, 723; SEDA-33, 841; SEDA-34, 653]

Prostaglandins and Analogues [SED-15, 2955; SEDA-31 SEDA-32, 729; SEDA-33, 846; SEDA-34, 660]

Chapter 40: Sex hormones and related compounds, including hormonal contraceptives
Abstract

Estrogens [SED-15, 1253; SEDA-32, 736; SEDA-33, 852; SEDA-34, 663]

Hormonal Contraceptives [SED-15, 1642; SEDA-32, 741; SEDA-33, 858; SEDA-34, 667]

Antiestrogens and Selective Estrogen Receptor Modulators (SERMs) [SEDA-32, 743; SEDA-33, 859; SEDA-34, 669]

Progestogens [SED-15, 2930; SEDA-32, 747; SEDA-33, 865; SEDA-34, 671]

Progesterone Antagonists [SEDA-32, 749; SEDA-33, 866; SEDA-34, 671]

Anabolic Steroids, Androgens, and Related Compounds [SED-15, 216; SEDA-32, 751; SEDA-33, 868; SEDA-34, 672]

Antiandrogens [SEDA-32, 755; SEDA-33, 872; SEDA-34, 674]

Chapter 41: Thyroid hormones, iodine and iodides, and antithyroid drugs
Abstract

Thyroid Hormones [SED-15, 3409; SEDA-32, 763; SEDA-33, 881; SEDA-34, 679]

Iodine and Iodides [SED-15, 1896; SEDA-32, 764; SEDA-33, 883; SEDA-34, 680]

Antithyroid Drugs [SED-15, 3387; SEDA-32, 765; SEDA-33, 884; SEDA-34, 681]

Chapter 42: Insulin, other hypoglycemic drugs, and glucagon
Abstract

Glucagon [SED-15, 1510; SEDA-32, 769; SEDA-33, 889]

Insulin [SED-15, 1761; SEDA-32, 769; SEDA-33, 889; SEDA-34, 685]

Alpha Glucosidase Inhibitors [SEDA-32, 772 SEDA-33, 893]

Amylin Analogues [SEDA-32, 773; SEDA-33, 893; SEDA-34, 687]

Biguanides [SED-15, 506; SEDA-32, 773; SEDA-33, 893; SEDA-34, 687]

Dipeptidyl Peptidase 4 (DDP-4) Inhibitors [SEDA-32, 774; SEDA-33, 894; SEDA-34, 688]

Incretin Mimetics [SEDA-32, 775; SEDA-33, 896; SEDA-34, 690]

Meglitinides [SED-15, 2238; SEDA-32, 776; SEDA-33, 897; SEDA-34, 694]

Sodium–Glucose Transporter Type 2 (SGLT2) Inhibitors [SEDA-33, 898; SEDA-34, 695]

Sulfonylureas [SED-15, 3230; SEDA-32, 777; SEDA-33, 898; SEDA-34, 695]

Thiazolidinediones (Glitazones) [SED-15, 3380; SEDA-32, 779; SEDA-33, 899; SEDA-34, 696]

Peroxisome Proliferator-Activated Receptor Partial Agonists

Peroxisome Proliferator-Activated Dual Receptor Agonists [SEDA-32, 782; SEDA-33, 902; SEDA-34, 698]

Chapter 43: Corticotrophins, corticosteroids, and prostaglandins
Abstract

Vasopressin Receptor Antagonists [SEDA-34, 713]

Vasopressin and Analogues [SED-15, 3609; SEDA-32, 798; SEDA-33, 915; SEDA-34, 714]

Chapter 44: Drugs that affect lipid metabolism
Abstract

Bile Acid Sequestrants [SED -15, 1902]

Cholesteryl Ester Transfer Protein Inhibitors [SEDA -32, 817; SEDA -33, 929; SEDA -34, 723]

Fibrates [SED -15, 1358; SEDA -32, 804; SEDA -33, 922; SEDA -34,724]

HMG-CoA Reductase Inhibitors [SED -15, 1632; SEDA -32, 807; SEDA -33, 924; SEDA -34, 725]

Nicotinic Acid Derivatives [SED -15, 2512; SEDA -32, 815; SEDA -33, 928; SEDA -34, 728]

Chapter 45: Cytostatic and cytotoxic drugs
Abstract

Chapter 46: Radiological contrast agents and radiopharmaceuticals
Abstract

MRI contrast media

Ultrasound contrast agents [SED-15, 3543; SEDA-32, 855; SEDA-33, 971; SEDA-34, 758]

Radiopharmaceuticals [SED-15, 3017; SEDA-33, 973; SEDA-34, 758]

Chapter 47: Drugs used in ocular treatment
Abstract

Drugs Used in the Management of Macular Degeneration [SEDA-32, 865; SEDA-33, 977; SEDA-34, 761]

Adrenoceptor Agonists [SEDA-32, 869; SEDA-33, 982; SEDA-34, 762]

Alpha-Adrenoceptor Agonists

Antibacterial Drugs

Anticholinergic Drugs [SEDA-34, 763]

Beta-Adrenoceptor Antagonists

Carbonic Anhydrase Inhibitors

Glucocorticosteroids [SED-15, 906; SEDA-32, 871; SEDA-33, 983; SEDA-34, 764]

Non-steroidal Anti-inflammatory Drugs [SEDA-34, 764]

Prostaglandin Analogues [SEDA-32, 871; SEDA-33, 984; SEDA-34, 764]

Devices and Procedures

Chapter 48: Treatments used in complementary and alternative medicine
Abstract

Asian Herbal Medicines [SED-15, 1609; SEDA-32, 879]

Nutritional Supplements

Specific Plants

Acupuncture

Chiropractic

Moxibustion

Chapter 49: Miscellaneous drugs, materials, medical devices, and techniques
Abstract

Dyestuffs [SEDA-32, 895; SEDA-33, 1016; SEDA-34, 791]

Sclerosants [SED-15, 3107; SEDA-33, 1021; SEDA-34, 795]

Index of drugs
Index of drug-drug interactions
Index of adverse effects and adverse reactions

The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia, Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading.

• Provides a critical yearly survey of new data and trends
• Special reviews in this Annual include, among other topics, epidemiology of the use of ecstasy, paracetamol and the risk of asthma, combination vaccines/multiple immunizations, interactions of herbal medicines with warfarin, and tyrosine kinase inhibitors

Pharmacologists, clinicians, pharmaceutical companies, clinical toxicologists, clinical pharmacologists and medical libraries